Thank you for submitting your abstracts!

• All abstracts must be submitted in clear and concise English. Spelling may be in US English or UK English.
• Abstracts must be from one of the ACCESS Competency and Learning categories:

1. Pricing
2. Access and Reimbursement
3. Evidence for Access
4. HTA Methods and Policy
5. Digital Health and AI
6. Patient Advocacy
7. MedTech
8. Experiential Learning

• Abstracts have a 3,500-character limit, including spaces. This excludes the title, authors, and images.
• Remove all track changes before submission, as copy-paste functions may retain them, making the abstract unreadable.
• Enter the title exactly as it should appear online in title case.
• Provide all co-author names and institutional affiliations at submission.

o Omissions cannot be added laterand will not be included in the
author block online or in the journal.

• The submitter is responsible for proofreading the abstract and the author list carefully.
• Tables and figures may be uploaded in a photo file format.
• Abstracts may be structured (e.g., Introduction, Methods, Results, Conclusions) or unstructured.
• Do not use bold or underline formatting—italicized text is permitted.
• Submitters may edit abstracts before the submission deadline.

o For changes after the deadline but before review, email
abstracts@marketaccess.org with the tracking number, abstract title,
and details of requested changes, including new author information.
o No changes are permitted once the review process has started.

• The presenting author of accepted abstracts for oral or poster presentations must attend the meeting in person. If unavailable, a co-author may present instead.

• Abstracts are reviewed by a panel of volunteer experts, assigned by the Head of the Scientific Committee.
• Reviewers evaluate abstracts based on:

o Research quality and presentation clarity
o Stregnth of results and methodology
o Impact on the field

• Abstracts that promote products/services or lack scientific or academic merit will be rejected.
• Each review committee consists of 3-5 expertsd specializing in the assigned category.
• Selected abstracts may be recommended for the Presidential Symposium or Clinical Trials Symposium, subject to further review by the Abstract Advisory Group (comprising the President, President-elect, Secretary, and selected reviewers)

General questions on abstract submission policies or notifications should be emailed to abstracts@marketaccess.org.